Good piece on why M&A should pick up substantially in 2019 across Biotech/Biopharma. Cash balances at drug giants continue to grow and they need to replenish their pipelines. Oncology should remain a core focal point for transactions. Good read...

Comments


Bret Jensen
EditorBret Jensen
Bret Jensen
EditorBret Jensen
Bret Jensen
EditorBret Jensen